Reuters examines global rise in drug-resistant tuberculosis cases

NewsGuard 100/100 Score

"[O]ften seen in the wealthy West as a disease of bygone eras," Reuters examines rising rates of tuberculosis (TB) -- drug-resistant TB in particular -- among the world's rich and poor. "[R]apidly rising rates of drug-resistant TB in some of the wealthiest cities in the world, as well as across Africa and Asia, are again making history," Reuters writes. According to the news service, "London has been dubbed the 'tuberculosis capital of Europe,' and a startling recent study documenting new cases of so-called 'totally drug-resistant' TB in India suggests the modern-day tale of this disease could get a lot worse."

"'We can't afford this genie to get out of the bag. Because once it has, I don't know how we'll control TB,' said Ruth McNerney, an expert on tuberculosis at the London School of Hygiene and Tropical Medicine," Reuters writes. The news service notes, "The WHO has convened a special meeting on Wednesday to discuss whether the emergence of TB strains that seem to be resistant to all known medicines merits a new class definition of 'totally drug-resistant TB,' or TDR-TB" (Kelland, 3/19).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
WHO releases an investment case for TB screening and preventive treatment